Personalized exercise shows promise for fatigue in rare blood cancers
NCT ID NCT07518940
First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This study tests whether a 12-week personalized exercise program can reduce fatigue and improve physical function in people with myeloproliferative neoplasms (MPN) and chronic myeloid leukemia (CML). Participants will do supervised aerobic and resistance training twice a week plus home exercise. The goal is to see if the program is safe, feasible, and helps with symptoms like fatigue and quality of life.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
supervised aerobic and resistance exercise program
What this could lead to
If successful, this could provide a safe, drug-free way to manage fatigue and improve quality of life for people with these rare blood cancers.
What could go wrong
This is a small, early feasibility study with only 25 participants, so results may not apply to everyone. Exercise may cause injury or other side effects, and benefits may not last after the program ends.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for POLYCYTHEMIA VERA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
AO Ordine Mauriziano di Torino
Torino, To, Italy
Contact Phone: •••-•••-•••• Email: •••••@•••••